---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-25-000028"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:51:10.426727+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q4 ZORYVE revenue $69.4M (+413% YoY); net loss narrows to $10.8M

## Summary
- Q4 total revenue $71.4M vs $13.5M YoY; net loss $0.09/share vs $0.72/share prior year.
- Full-year ZORYVE net product revenue $166.5M (+471% YoY); ZORYVE is #1 branded non-steroidal topical in U.S.
- Submitted sNDA for ZORYVE cream 0.05% for atopic dermatitis in children ages 2-5; target action Q4 2025.
- Prepaid $100M of $200M term loan; maintains ability to re-draw; cash & securities $228.6M at year-end.
- ZORYVE foam for scalp/body psoriasis PDUFA date May 22, 2025; partnered with Odell Beckham Jr. for seborrheic dermatitis awareness.

## SEC filing metadata
- accession: 0001787306-25-000028
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000028/0001787306-25-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000028/arqt-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-25-000028
- JSON: https://secwatch.observer/filing/0001787306-25-000028.json
- Plain text: https://secwatch.observer/filing/0001787306-25-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.